LI
BCRX icon

Leap Investments’s BioCryst Pharmaceuticals BCRX Stock Holding History

Leap Investments’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		$311K Buy
+65,200
New +$260K 0.2% 197

Other funds holding BCRX

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Leap Investments's BCRX Position: Q2 2020 in Review

Leap Investments opened a new position in BioCryst Pharmaceuticals (BCRX) in Q2 2020: 65,200 shares worth $311K. The stake represents 0.2% of the portfolio and ranks #197 among its holdings.

165 funds tracked by Wall St. Rank hold BCRX as of Q2 2020.

  • Leap Investments held 65,200 shares of BioCryst Pharmaceuticals worth $311K as of Q2 2020.
  • BioCryst Pharmaceuticals was a new Leap Investments position in Q2 2020.
  • BioCryst Pharmaceuticals made up 0.2% of Leap Investments's portfolio in Q2 2020, its #197 holding.
  • 165 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2020.

Based on Leap Investments's 13F filing for Q2 2020, filed 3 Aug 2020.